Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$3.24 USD
-0.07 (-2.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Kyverna Therapeutics, Inc.'s return on equity, or ROE, is -51.66% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that KYTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
KYTX 3.24 -0.07(-2.11%)
Will KYTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYTX
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise | ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer | KYTX Stock News
Kyverna Therapeutics names Marc Grasso, M.D., as CFO